Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: reduced folate and rescue pharmacology
Also known as: Calcium folinate, Leucovorin calcium
Calcium folinate (leucovorin calcium, folinic acid) is a reduced folate derivative that, unlike folic acid, does not require dihydrofolate reductase (DHFR) conversion to become active tetrahydrofolate. Its best-established clinical use is as a 'rescue' agent given roughly 24 hours after high-dose methotrexate chemotherapy, replenishing reduced-folate pools in normal cells to limit methotrexate's antifolate toxicity. It is also combined with 5-fluorouracil (5-FU) in colorectal cancer regimens (e.g., FOLFOX, FOLFIRI), where it stabilizes the FdUMP-thymidylate synthase complex and thereby enhances 5-FU's antineoplastic activity. Additional approved uses include treatment of megaloblastic anemia from folate deficiency when oral therapy isn't feasible, and reversal of toxicity from folic-acid-antagonist drugs such as trimethoprim or pyrimethamine. Leucovorin is an FDA-approved prescription drug with an extensive clinical and pharmacokinetic literature base (StatPearls, DrugBank, numerous oncology trial protocols).
Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.
Data source: Approved leucovorin labeling
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.
15 mg every six hours for ten doses beginning 24 hours after methotrexate
Context: leucovorin calcium prescribing information
Formulation: Oral-mucosal formulations are not dose-equivalent to injectable or topical formulations.
Route safety: Use only in the cited label or guideline context; route, formulation, indication, and patient-specific limits still apply.
No route-specific amount established in the reviewed record.
Context: The catalog identifies this route, but its reviewed sources do not establish a separate amount and schedule for it.
Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.
Route safety: No route-specific protocol is established. Do not infer an amount from another route, component, or formulation.
No route-specific amount established in the reviewed record.
Context: The catalog identifies this route, but its reviewed sources do not establish a separate amount and schedule for it.
Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.
Route safety: No route-specific protocol is established. Do not infer an amount from another route, component, or formulation.
Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.
Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.
The unsupported MTHFR-bypass supplement protocol was removed. This is an approved pharmaceutical whose rescue dose depends on methotrexate exposure and laboratory monitoring.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.